NCT06793904 Comparative Study Between HOMA1-IR and HOMA2-IR in Prediction of Ovulation Outcome in Women With PCOS
| NCT ID | NCT06793904 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Polycystic Ovarian Syndrome (PCOS) |
| Study Type | INTERVENTIONAL |
| Enrollment | 122 participants |
| Start Date | 2025-02-01 |
| Primary Completion | 2026-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 122 participants in total. It began in 2025-02-01 with a primary completion date of 2026-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
122 women diagnosed with PCOS seeking fertility in the fertility clinic at kasr Alainy hospital will be subjected to Homeostatic model assessment for insulin resistance 1 was calculated for all participants through the equation \[glucose (mmol/L) × insulin (µU/L)\]/22.5 while homeostatic model assessment for insulin resistance 2 was calculated by the HOMA2 calculator. All women will be subjected to induction of ovulation using the Aromatase inhibitor Letrozole 2.5 mg tab twice daily from the 3rd day of the cycle for 5 days . Ultrasound follow up of follicular growth will be performed till dominant follicular size reaches 18-22 mm. FSH preparations will be introduced as needed.
Eligibility Criteria
Inclusion Criteria: * Age 18-35 years * duration of infertility 1-4 years * PCOS Exclusion Criteria: women with other causes of infertility (tubal factor assessed by laparoscopy or hysterosalpingogram, uterine cavity abnormality assessed by ultrasound or hysteroscopy or male factor assessed by seme analysis), * endometriosis, * ovarian cysts, * endocrinological abnormalities (Diabetes mellitus, hypothalamic, pituitary or thyroid disorders, or hyperprolactinemia), * women with history of poor ovarian response or ovarian hyperstimulation * women with chronic diseases, chromosomal, autoimmune or coagulation defects, abnormal leucocytic count or other inflammatory markers * Women with contraindications to pregnancy.
Contact & Investigator
Ahmed Maged, MD
PRINCIPAL INVESTIGATOR
Cairo University
Frequently Asked Questions
Who can join the NCT06793904 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 35 Years, studying Polycystic Ovarian Syndrome (PCOS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06793904 currently recruiting?
Yes, NCT06793904 is actively recruiting participants. Contact the research team at dr_ahmedmaged08@kasralainy.edu.eg for enrollment information.
Where is the NCT06793904 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06793904 clinical trial?
NCT06793904 is sponsored by Cairo University. The principal investigator is Ahmed Maged, MD at Cairo University. The trial plans to enroll 122 participants.